A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma | Zendy

Chia-Jui Yen | Zendy; TaeYou Kim | Zendy; YinHsun Feng | Zendy; Yee Chao | Zendy; DengYn Lin | Zendy; BaekYeol Ryoo | Zendy; Dennis Huang | Zendy; David Schnell | Zendy; Julia Hocke | Zendy; ArsèneBienvenu Loembé | Zendy; AnnLii Cheng | Zendy

Open Access

A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma

Author(s) -

Chia-Jui Yen,

TaeYou Kim,

YinHsun Feng,

Yee Chao,

DengYn Lin,

BaekYeol Ryoo,

Dennis Huang,

David Schnell,

Julia Hocke,

ArsèneBienvenu Loembé,

AnnLii Cheng

Publication year - 2018

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000486460

Subject(s) - nintedanib , sorafenib , hepatocellular carcinoma , pharmacokinetics , medicine , oncology , phases of clinical research , pharmacology , clinical trial , lung , idiopathic pulmonary fibrosis

Nintedanib is an oral, triple angiokinase inhibitor of vascular endothelial growth factor/platelet-derived growth factor/fibroblast growth factor receptors. This randomized, multicenter, open-label, phase I/II study evaluated the safety, pharmacokinetics, maximum tolerated dose (MTD) in terms of dose-limiting toxicities (DLTs), and efficacy of nintedanib versus sorafenib in Asian patients with unresectable advanced hepatocellular carcinoma (HCC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research